• 02/01/2023 – 01/01/2025

CYTIDES (CODEVELOP-ICT-HEALTH/0322/0038) brought together, for the first time in Cyprus, academia and an API manufacturer to co-develop generic therapeutic peptides.

The project united BIOGENA API and the Laboratory of Peptide Chemistry – University of Nicosia Research Foundation (UNRF) to develop more sustainable, scalable, and cost-effective manufacturing approaches using Green Chemistry principles.

Three therapeutic peptides were investigated: Liraglutide, Etelcalcetide, and Teriparatide, covering synthesis, process optimization, scale-up, and industrial feasibility.

Liraglutide was successfully scaled up using Biogena’s microwave synthesis platform, with three independent batches demonstrating robust and reproducible performance. The project also generated valuable knowledge in peptide synthesis, purification, analytical methodologies, impurity profiling, and sustainable manufacturing, supporting future peptide development and industrial scale-up.

‘The Project is funded by the European Union – NextGenerationEU, through the Research and Innovation Foundation’

• 15/07/2022-29/04/2024

Biogena (A.P.I) LTD has earned within the contexts of the operational program «Θ.Αλ.Ε.Ι.Α» 2021-2027 a public funding for the implementation of it. Through this program, the company will invest in the purchase of new LC-MS/MS.

‘The Project is funded by the European Union through the Ministry of Energy, Commerce and Industry’

• 14/12/2022-13/06/2023

Green techniques in peptide synthesis, INNOVOUCHER/0722/0009

Biogena A.P.I Ltd in collaboration with the Laboratory of Peptide Chemistry – University of Nicosia Research Foundation – UNRF have been funded for a project under the Technological Development and Innovation “RESTART 2016 – 2020”.

‘The Project is funded by the European Union – NextGenerationEU, through the Research and Innovation Foundation’

• Innovative drug formulation for targeted release of Rifaximin based on polymer nanotechnology (INNOVATE/0719/0083)

Biogena A.P.I Ltd in collaboration with Medochemie Ltd (a generic pharmaceutical company) have been funded for a project under the Technological Development and Innovation “RESTART 2016 – 2020”.

‘The Project is funded by the European Union – NextGenerationEU, through the Research and Innovation Foundation’